Evogene Ltd. (EVGN)
| Bid | 1 |
| Market Cap | 6.47M |
| Revenue (ttm) | 8.51M |
| Net Income (ttm) | -16.48M |
| EPS (ttm) | -2.89 |
| PE Ratio (ttm) | -0.34 |
| Forward PE | -0.72 |
| Analyst | Buy |
| Ask | 1.07 |
| Volume | 13,886 |
| Avg. Volume (20D) | 21,367 |
| Open | 0.98 |
| Previous Close | 1.00 |
| Day's Range | 0.95 - 0.98 |
| 52-Week Range | 0.95 - 9.00 |
| Beta | 1.18 |
About EVGN
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover...
Analyst Forecast
According to 1 analyst ratings, the average rating for EVGN stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 1137.11% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
EverGen Infrastructure Provides Operations and Development UpdatesVANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQX: EVGIF), announces operational updates at its Pacific Coast Renewables (“PCR...